Look under a pharma executive's bed, and you'll find monsters. What do those monsters look like, though? Accenture talked to C-suite executives at the world's biggest drugmakers and found that some of yesteryear's scary beings have moved on, leaving others to take front and center.
GlaxoSmithKline has rolled out a slew of respiratory meds lately, looking for newcomers to take up the torch as Advair sales fade. After notching three approvals on the COPD side, now, the pharma giant has a brand new asthma treatment on its hands in Arnuity.
GlaxoSmithKline's banner respiratory division picked up another FDA approval, securing the agency's blessing for an inhaled asthma treatment as it expands its stable of drugs for airway disorders.
The second round of bidding for a portfolio of aging GlaxoSmithKline drugs is about to begin, and a bevy of big names is expected to participate. The product portfolio--which includes such drugs as Paxil for depression, the antimalarial Malarone, and the fish-oil based Lovaza--brings in about £1 billion ($1.7 billion) in annual sales.
As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.
GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.
Scientists thought they may have been on to something as far as deciphering the link between GlaxoSmithKline's pandemic swine flu vaccine and narcolepsy. But now, unable to replicate their findings, they've retracted the study.
Last month, a whistleblower sent a letter to GlaxoSmithKline alleging "multiple corrupt and illegal practices" in the company's Syrian consumer health operation before it was shut down in 2012. Now it appears the problems may have extended to GSK's prescription drug business in Syria, which is still in operation.
British drugmaker GlaxoSmithKline says it is ready to begin clinical trials on an Ebola vaccine later this year and could have the vaccine available by 2015.
It took GlaxoSmithKline 30 years to get its new malaria vaccine ready for regulatory review. But global health officials--driven by a worldwide clamor--are excitedly pointing to GSK now as one of its prime candidates for getting a vaccine to fight Ebola in a matter of months.